Fintech PR
AMD Unveils Purpose-Built, FPGA-Based Accelerator for Ultra-Low Latency Electronic Trading
— New AMD Alveo fintech accelerator card provides trading firms and brokerages with breakthrough trade execution performance at nanosecond speed and AI-enabled trading strategies —
— Solution partners Alpha Data, Exegy and Hypertec add to growing ecosystem of ultra-low latency solutions for fintech market —
LONDON, Sept. 29, 2023 /PRNewswire/ — AMD (NASDAQ: AMD) today announced the AMD Alveo™ UL3524 accelerator card, a new fintech accelerator designed for ultra-low latency electronic trading applications. Already deployed by leading trading firms and enabling multiple solution partner offerings, the Alveo UL3524 provides proprietary traders, market makers, hedge funds, brokerages, and exchanges with a state-of-the-art FPGA platform for electronic trading at nanosecond (ns) speed.
The Alveo UL3524 delivers a 7X latency improvement over prior generation FPGA technology1, achieving less than 3ns FPGA transceiver latency2 for accelerated trade execution. Powered by a custom 16nm Virtex™ UltraScale™+ FPGA, it features a novel transceiver architecture with hardened, optimized network connectivity cores to achieve breakthrough performance. By combining hardware flexibility with ultra-low latency networking on a production platform, the Alveo UL3524 enables faster design closure and deployment compared to traditional FPGA alternatives.
“In ultra-low latency trading, a nanosecond can determine the difference between a profitable or losing trade,” said Hamid Salehi, director of product marketing at AMD. “The Alveo UL3524 accelerator card is powered by the lowest latency FPGA transceiver from AMD—purpose-built to give our fintech customers an unprecedented competitive advantage in financial markets.”
Hardware Flexibility and AI-Enabled Trading Strategies
Featuring 64 ultra-low latency transceivers, 780K LUTs of FPGA fabric, and 1,680 DSP slices of compute, the Alveo UL3254 is built to accelerate custom trading algorithms in hardware, where traders can tailor their design to evolving strategies and market conditions. Supported by traditional FPGA flows using Vivado™ Design Suite, the product comes with a suite of reference designs and performance benchmarks that allow FPGA designers to quickly explore key metrics and develop custom trading strategies to specification, backed by global support from AMD domain experts.
To simplify the increasing adoption of AI in the algorithmic trading market, AMD is providing developers with the open-sourced and community-supported FINN development framework. By using PyTorch and neural network quantization techniques, the FINN project enables developers to reduce the size of the AI models while retaining accuracy, compiling to hardware IP, and integrating the network model into the algorithm’s datapath for low latency performance. As an open-source initiative, the solution gives developers flexibility and accessibility to the latest advancements as the projects evolve.
Enabling a Growing Ecosystem of Ultra-Low Latency Fintech Solutions
The Alveo UL3524 and purpose-built FPGA technology are enabling strategic partners to build custom solutions and infrastructure for the fintech market. Currently available partner solutions include offerings from Alpha Data, Exegy, and Hypertec.
The AMD Virtex™ UltraScale+ VU2P FPGA powering the Alveo UL3524 accelerator card is enabling ultra-low latency appliances from Alpha Data.
“The new Virtex UltraScale+ FPGA from AMD brings a step change to ultra-low latency trading and networking,” said David Miller, managing director of Alpha Data. “We’ve developed the ADA-R9100 rack-mount appliance which allows customers to easily access the full potential of the new AMD FPGA device.”
Exegy, a provider of end-to-end, front-office trading solutions, is supporting the Alveo UL3524 card with its nxFramework, a software and hardware development environment tailored for creating and maintaining ultra-low latency FPGA applications within the financial industry.
“By combining the pioneering ultra-low latency FPGA technology from AMD with Exegy’s expertise in capital markets, we’re able to deliver a comprehensive solution that addresses the ever-increasing optimization needed to build the trading infrastructure of tomorrow,” said Olivier Cousin, director of FPGA solutions at Exegy.
Hypertec has optimized its ORION HF X410R-G6 High Frequency Server for the Alveo UL3524 with a custom cooling system to deploy in a 1U server form factor.
“The engineers at Hypertec specifically designed the HF X410R-G6 to extract the best out of the capabilities and speed of the Alveo UL3524 platform, catering our solution to the most demanding low-latency tasks,” said David Lim, director of product marketing, Hypertec.
The AMD Alveo UL3524 accelerator card is currently in production and shipping to global financial services customers.
Supporting Resources
- Learn more about the Alveo UL3524 accelerator card
- Become a fan of AMD on Facebook
- Follow AMD on Twitter
About AMD
For more than 50 years AMD has driven innovation in high-performance computing, graphics, and visualization technologies. Billions of people, leading Fortune 500 businesses, and cutting-edge scientific research institutions around the world rely on AMD technology daily to improve how they live, work, and play. AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website, blog, LinkedIn, and Twitter pages.
AMD, the AMD Arrow logo, Alveo, Virtex, Vivado and combinations thereof are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.
1 Testing conducted by AMD Performance Labs as of 8/16/23 on the Alveo UL3524 accelerator card, using Vivado™ Design Suite 2023.1 and running on Vivado Lab (Hardware Manager) 2023.1. Based on the GTF Latency Benchmark Design configured to enable GTF transceivers in internal near-end loopback mode. GTF TX and RX clocks operate at same frequency of ~644MHz with a 180 degrees phase shift. GTF Latency Benchmark Design measures latency in hardware by latching value of a single free running counter. Latency is measured as the difference between when TX data is latched at the GTF transceiver and when TX data is latched at the GTF receiver prior to routing back into the FPGA fabric. Latency measurement does not include protocol overhead, protocol framing, programmable logic (PL) latency, TX PL interface setup time, RX PL interface clock-to-out, package flight time, and other sources of latency. Benchmark test was run 1,000 times with 250 frames per test. Cited measurement result is based on GTF transceiver “RAW Mode”, where PCS (physical medium attachment) of the transceiver passes data ‘as-is’ to FPGA fabric. Latency measurement is consistent across all test runs for this configuration. System manufacturers may vary configurations, yielding different results. ALV-10
2 Based on simulation comparison between Virtex UltraScale+ GTY transceivers and ultra-low latency GTF transceivers.
View original content:https://www.prnewswire.co.uk/news-releases/amd-unveils-purpose-built-fpga-based-accelerator-for-ultra-low-latency-electronic-trading-301943169.html
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News4 days ago
Letter from Gatemore Capital Management LLP to Elementis PLC
-
Latest News7 days ago
Money20/20 Asia 2024: Days Two Roundup
-
Latest News4 days ago
Shanghai Electric Releases ESG Report, Highlighting Sustainable Development Achievements in 2023
-
Latest News7 days ago
Stripe Unveils Unbundled Payments Strategy in Fintech Pivot
-
Latest News3 days ago
Hyosung Heavy Industries Ranked on BNEF’s Energy Storage Tier 1 List
-
Latest News7 days ago
Zafin Unveils Strategic Leadership Transition in Canadian SaaS Fintech
-
Latest News6 days ago
Former Tesla executive Tim Newell is set to spin off Aspiration’s consumer financial services division.
-
Latest News6 days ago
United Imaging Healthcare releases 2023 annual report, with revenue growth of 23.52%